Berberine (1), an isoquinoline alkaloid, was isolated from the golden seal, Hydratis canadensis L., a member of the family Ranunculaceae, and also occurs in many other plants including the Berberies species (Berberidaceae) and Arcangelisia flora (Memnispermaceae).
Berberine (1), an isoquinoline alkaloid, was isolated from the golden seal, Hydratis canadensis L., a member of the family Ranunculaceae, and also occurs in many other plants including the Berberies species (Berberidaceae) and Arcangelisia flora (Memnispermaceae).
2) The pharmacological and antibacterial properties of berberine (1) have been extensively studied and it is widely used as a stomachic and antidiarrhetic, 3) and is also a potent inhibitor of thymocyte apoptosis. 4) In a search for active constituents of the kampo formula, tsu-kan-gan, which inhibits bone resorption, berberine (1) was found to have an inhibitory activity against ovariectomized (OVX) rats as a postmenopausal osteoporosis model. 5) Involutional osteoporosis is of two types: Type-1, known as postmenopausal osteoporosis, occurs in women after menopause, and Type-2, known as senile osteoporosis, occurs in both men and women over 70 years of age. 6) For the former, OVX rats have been used as an experimental model, while senescence accelerated mice P6 (SAMP6) can be used as a senile osteoporosis model. 7) The present studies investigated the effect of berberine (1) on bone mineral density (BMD) in SAMP6, the body and tibia weights, and the concentration of deoxypyridinoline (Dpd) and procollagen type I carboxyterminal extension peptide (PICP).
MATERIALS AND METHODS

Animal Protocol
Male and female SAMP6 (six-weeks old) were devided into two groups of eight to ten animals. Group 1 (control group) was given water, whereas group 2 was given berberine. Berberine was suspended in distilled water, and was administered orally for 22 weeks at a dose of 10 mg/kg/d. At the end of the experimental period, urine samples were collected to measure Dpd. BMD values were measured in the lumbar vertebrae using dual energy X-ray absorptiometry (DXA). The right tibia were excised and immediately weighed. Blood samples were collected from the heart and the serum was separated and used to analyze PICP.
Dpd Assay The excretion of Dpd, a marker of bone resorption, was measured in the urine samples and analysis was performed according to published procedures of chemiluminescence immunoassay. 8) Briefly, the urine sample was centrifuged and stored at Ϫ20°C until assayed. The enzyme immunoassay (EIA) method for Dpd (pyrilinks-D assay, Metra Biosystems, Inc.) is competitive, and performed in a microplate well strip format, utilizing a monoclonal anti-Dpd antibody coated on the strip to capture Dpd. First, the urinary samples (or standard) with Dpd-alkaline phosphatase were placed in a well, then reacted for two hours in the dark. The well was washed, p-nitrophenylphosphate substrate was added and the captured conjugated Dpd-alkaline phosphatase reaction product was measured at 405 nm. Results are expressed in nanomoles and normalized for the urinary concentration of creatinine, which was determined by an alkaline picrate method.
PICP Assay The serum PICP, a marker for bone formation, was measured 22 weeks after the end of the experiment in serum samples; analysis was performed according to published procedures. 9) Briefly, a blood sample was centrifuged at 2000ϫg for 15 min to obtain serum and stored at Ϫ20°C until assayed. An RIA with polyclonal antibodies against the PICP purified from human skin fibroblasts was used (Orion Diagnostica). The antibody used did not react with fragments of collagens. First, the serum samples or standards with the tracer solution and the diluted antiserum were incubated for 2 h at 37°C, and the second antibody was added. After 30 min at room temperature, the bound fraction was separated by centrifugation. The supernate containing the unbound tracer was decanted, and the radioactivity of the precipitate containing the bound tracer was counted.
Statistics All values were expressed as the meanϮ S.E.M. of 8-10 animals. Significance of the mean differences in each experiment was analyzed by Student's t-test, and a p value of Ͻ0.05 was considered significant. The effects of berberine in senescence accelerated mice P6 (SAMP6) were investigated to learn whether the alkaloid affects bone mineral density (BMD). Oral administration of berberine (10 mg/kg/d) to male and female mice for 22 weeks resulted in an increase in BMD in both sexes. A decreased concentration of deoxypyridinoline (Dpd) in urine was only observed in female mice. There was no effect on body or tibia weight or on the concentration of procollagen type I carboxyterminal extension peptide (PICP) in serum.
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Key words berberine; senescence accelerated mice P6 (SAMP6); bone mineral density (BMD); deoxypyridinoline (Dpd); procollagen type I carboxyterminal extension peptide (PICP) Fig. 1 . Chemical Structure of Berberine (1) RESULTS AND DISCUSSION We reported previously that berberine (1) prevented ovariectomy-related bone loss in OVX rats after oral administration for 4 weeks at concentrations of 30 and 50 mg/kg/d. It also inhibited both the formation of osteoclasts (OCLs) and the bone-resorbing activity of OCLs in vitro. 5) In studies of osteoporosis, OVX rats are usually used as experimental animals 10) for the study of postmenopausal osteoporosis. The present studies investigated the effect of berberine (1) on BMD in SAMP6 which can be used as a senile osteoporosis model. 7) Senile osteoporosis primarily results from age-related bone loss, implying that net bone resorption exceeds net bone formation.
11) Traditionally, age-related bone loss has been attributed to impaired vitamin D activation and decreased calcium absorption. 12) When berberine (1) was orally administered at a concentration of 10 mg/kg/d, it significantly improved BMD in both male and female mice compared with the control group (Table 1) , but had no effect on body or tibia weight. This indicates that berberine prevents bone loss in senile osteoporosis.
To assess the effect of berberine in bone turnover, we measured two biochemical markers, Dpd and PICP. Bone turnover is characterized both by the formation of new bone by osteoblasts and the resorption of old tissue by osteoclasts. 13) Dpd is a cross link of bone collagen, which is released and excreted in urine during the process of bone resorption. It has been shown that this bone collagen degradation product, Dpd, is a useful diagnostic marker of osteoporosis and other metabolic bone diseases, 14) while PICP is significantly correlated with rates of bone deposition and can be used as a sensitive indicator of bone formation. Bone formation markers indicate osteoblast activity. 15) Measurement of the concentrations of Dpd showed that berberine (1) significantly decreased it only in female mice but not in males, and did not influence the concentration of PICP in either sex ( Table 2 ). The level of Dpd in females was significantly higher than in males, indicating that Dpd is more sensitive to change in females than in males. 16) As reported, berberine (1) prevented a decrease in BMD in OVX rats and inhibited both the formation of OCLs and its bone-resorbing activity in vitro.
5) Therefore, it is suggested that berberine (1) may inhibit bone resorption through OCLs in females, thus inhibiting bone decrease. Berberine (1) decreased the bone loss of males, however, perhaps through a different pathway; this requires further discussion.
In conclusion, our results indicate that berberine (1) inhibits BMD decrease in both male and female SAMP6, and also decreases the concentration of Dpd in female mice. 
